FDA accepts Seattle Genetics' lymphoma drug Adcetris for review

05/16/2013 | Bloomberg Businessweek · PharmaTimes (U.K.)

The FDA has accepted Seattle Genetics' supplemental biologics license application for the use of Adcetris, or brentuximab vedotin, for retreatment and use beyond 16 cycles of therapy in patients with relapsed Hodgkin lymphoma and systemic anaplastic large cell lymphoma. A decision is expected by Sept. 14.

View Full Article in:

Bloomberg Businessweek · PharmaTimes (U.K.)

Published in Briefs:

SmartBrief Job Listings for Health Care

Job Title Company Location
Senior or Principal Consultant
PAREXEL International
Nationwide, SL_Nationwide
Santa Ana, CA
Senior Financial Analyst - Growing Manager Care Health Org
Fallon Community Health Plan
Worcester, MA
Assistant General Counsel, Regulatory
Cardinal Health
Waukegan, IL
Chief Executive Officer
UCare Minnesota
Minneapolis, MN